|
|
||||||||||||||
|
|
|||||||||||||||
|
British Journal of Ophthalmology 2006;90:5-6; doi:10.1136/bjo.2005.079889 Copyright © 2006 by the BMJ Publishing Group Ltd.
Thrombospondin in the eyeJ M Stewart
Correspondence to:
A regulator of angiogenesis
Keywords: thrombospondin; age related macular degeneration; extracellular matrix; Bruchs membrane
Research into the pathophysiology of age related macular degeneration (AMD) has advanced at a rapid rate in recent years. To see the pace of progress, one need only pick up any issue of a major ophthalmic journal or attend a poster session at an ophthalmic society meeting. Efforts are under way to learn more about the ageing of Bruchs membrane, drusen formation, and angiogenesis in choroidal neovascularisation (CNV). And its beginning to pay off: our understanding of these mechanisms has led to some promising new treatments, particularly in the area of angiogenesis.
In the case of CNV, much of the focus lately has been on pro-angiogenic proteins such as vascular endothelial growth factor (VEGF). Treatment strategies that target pathologically elevated levels of VEGF are easy to understand: they try to block or reduce a known stimulus for the growth of CNV. Some early successes have been
Related Article
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |